Beneficial Ownership Report · SCHEDULE 13G
Immunome, Inc.
IMNMNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Immunome, Inc.
- Company CIK
- 0001472012
- Street
- 18702 North Creek Parkway,
- Street (continued)
- Suite 100
- City
- Bothell
- State / country code
- X1
- Postal code
- NA
Statement details
- Security class
- Common Stock
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- Wellington Management Group LLP
- Citizenship / organization
- MA
- Reporting person type
- HC
- Aggregate amount owned
- 6,041,333.00
- Percent of class
- 5.3
- Sole voting power
- 0
- Shared voting power
- 5,696,467
- Sole dispositive power
- 0
- Shared dispositive power
- 6,041,333
Reporting person 2
- Name
- Wellington Group Holdings LLP
- Citizenship / organization
- DE
- Reporting person type
- HC
- Aggregate amount owned
- 6,041,333.00
- Percent of class
- 5.3
- Sole voting power
- 0
- Shared voting power
- 5,696,467
- Sole dispositive power
- 0
- Shared dispositive power
- 6,041,333
Reporting person 3
- Name
- Wellington Investment Advisors Holdings LLP
- Citizenship / organization
- DE
- Reporting person type
- HC
- Aggregate amount owned
- 6,041,333.00
- Percent of class
- 5.3
- Sole voting power
- 0
- Shared voting power
- 5,696,467
- Sole dispositive power
- 0
- Shared dispositive power
- 6,041,333
Reporting person 4
- Name
- Wellington Management Company LLP
- Citizenship / organization
- DE
- Reporting person type
- IA
- Aggregate amount owned
- 6,041,333.00
- Percent of class
- 5.2
- Sole voting power
- 0
- Shared voting power
- 5,695,111
- Sole dispositive power
- 0
- Shared dispositive power
- 5,872,919
Item 1
Issuer
Immunome, Inc.
Principal executive office address
18702 North Creek Parkway,, Suite 100, Bothell WA
Item 2
Citizenship
Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
Filing person
Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
Principal business or residence address
c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
Item 3
Not applicable indication
N
Type of filing person
HC · IA
Item 4
Percent of class
5.32
Amount beneficially owned
See the responses to Item 9 on the attached cover pages.
Sole voting power
0
Shared voting power
See the responses to Item 6 on the attached cover pages.
Sole dispositive power
0
Shared dispositive power
See the responses to Item 8 on the attached cover pages.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
Item 7
Not applicable indication
N
Subsidiaries
Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- Wellington Management Group LLP
- Signed
- Matthew Revell
- Title
- Compliance Manager
- Date
- 11/16/2026
Signature 2
- Reporting person
- Wellington Group Holdings LLP
- Signed
- Matthew Revell
- Title
- Compliance Manager
- Date
- 11/16/2026
Signature 3
- Reporting person
- Wellington Investment Advisors Holdings LLP
- Signed
- Matthew Revell
- Title
- Compliance Manager
- Date
- 11/16/2026
Signature 4
- Reporting person
- Wellington Management Company LLP
- Signed
- Matthew Revell
- Title
- Compliance Manager
- Date
- 11/16/2026
Filed exhibits
- JOINT FILING AGREEMENT ↗Rule13D_JointFilingAgreement.htm
Company context
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA and an MAA has been validated by the EMA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; IM-3050, a clinical-stage FAP-targeted radioligand therapy; and IM-1340, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.